FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements - Bekaii-Saab, TS; Valle, JW; Van Cutsem, E (Future Oncol, 2020)
et al.